The validation of cardiovascular risk scores for patients with type 2 diabetes mellitus

被引:56
|
作者
van der Leeuw, J. [1 ]
van Dieren, S. [2 ,3 ]
Beulens, J. W. J. [2 ]
Boeing, H. [4 ]
Spijkerman, A. M. W. [5 ]
van der Graaf, Y. [2 ]
van der A, D. L. [5 ]
Noethlings, U. [6 ]
Visseren, F. L. J. [1 ]
Rutten, G. E. H. M. [2 ]
Moons, K. G. M. [2 ]
van der Schouw, Y. T. [2 ]
Peelen, L. M. [2 ]
机构
[1] Univ Med Ctr Utrecht, Dept Vasc Med, NL-3508 GA Utrecht, Netherlands
[2] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, NL-3508 GA Utrecht, Netherlands
[3] Univ Amsterdam, Acad Med Ctr, Clin Res Unit, NL-1105 AZ Amsterdam, Netherlands
[4] German Inst Human Nutr Potsdam Rehbrucke, Dept Epidemiol, Nuthetal, Germany
[5] Natl Inst Publ Hlth & Environm RIVM, Ctr Nutr Prevent & Hlth Serv, Bilthoven, Netherlands
[6] Univ Bonn, Dept Nutr & Food Sci, Bonn, Germany
关键词
CORONARY-HEART-DISEASE; EXTERNAL VALIDATION; PREDICTION MODELS; VASCULAR-DISEASE; FRAMINGHAM; ENGINE; DERIVATION; EQUATIONS; EVENTS; PEOPLE;
D O I
10.1136/heartjnl-2014-306068
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective Various cardiovascular prediction models have been developed for patients with type 2 diabetes. Their predictive performance in new patients is mostly not investigated. This study aims to quantify the predictive performance of all cardiovascular prediction models developed specifically for diabetes patients. Design and methods Follow-up data of 453, 1174 and 584 type 2 diabetes patients without pre-existing cardiovascular disease (CVD) in the EPIC-NL, EPIC-Potsdam and Secondary Manifestations of ARTerial disease cohorts, respectively, were used to validate 10 prediction models to estimate risk of CVD or coronary heart disease (CHD). Discrimination was assessed by the c-statistic for time-to-event data. Calibration was assessed by calibration plots, the Hosmer-Lemeshow goodness-of-fit statistic and expected to observed ratios. Results There was a large variation in performance of CVD and CHD scores between different cohorts. Discrimination was moderate for all 10 prediction models, with c-statistics ranging from 0.54 (95% CI 0.46 to 0.63) to 0.76 (95% CI 0.67 to 0.84). Calibration of the original models was poor. After simple recalibration to the disease incidence of the target populations, predicted and observed risks were close. Expected to observed ratios of the recalibrated models ranged from 1.06 (95% CI 0.81 to 1.40) to 1.55 (95% CI 0.95 to 2.54), mainly driven by an overestimation of risk in high-risk patients. Conclusions All 10 evaluated models had a comparable and moderate discriminative ability. The recalibrated, but not the original, prediction models provided accurate risk estimates. These models can assist clinicians in identifying type 2 diabetes patients who are at low or high risk of developing CVD.
引用
收藏
页码:222 / 229
页数:8
相关论文
共 50 条
  • [31] Endocan is Related to Increased Cardiovascular Risk in Type 2 Diabetes Mellitus Patients
    Klisic, Aleksandra
    Kotur-Stevuljevic, Jelena
    Ninic, Ana
    METABOLIC SYNDROME AND RELATED DISORDERS, 2023, 21 (07) : 362 - 369
  • [32] Expression of miRNAs as a marker for cardiovascular risk in patients with type 2 diabetes mellitus
    Gateva, P.
    Mihaleva, I.
    Kamenova, K.
    Giragosyan, S.
    Dodova, R.
    Kaneva, R.
    Dimova, I.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2020, 28 (SUPPL 1) : 852 - 853
  • [33] Coronary Calcium Scoring and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus
    Vicente Sanchez, Belkis M.
    Zerquera Trujillo, Gisela
    Jorrin Roman, Felix. R.
    de la Cruz Avilez, Lazaro E.
    Alpizar, Elodia M. Rivas
    MEDISUR-REVISTA DE CIENCIAS MEDICAS DE CIENFUEGOS, 2011, 9 (01): : 73 - 78
  • [34] DYSLIPIDEMIA AND CARDIOVASCULAR RISK FACTORS IN A SAMPLE OF PATIENTS WITH TYPE 2 DIABETES MELLITUS
    Guerra Ruiz, A. R.
    Lavin Gomez, B. A.
    Garcia Unzueta, M. T.
    Hernandez Hernandez, L. A.
    Vazquez Salvi, L. A.
    Vazquez de Prada, J. A.
    Garrido Gomez, J. C.
    ATHEROSCLEROSIS, 2018, 275 : E217 - E217
  • [36] Effects of Liraglutide on Cardiovascular Risk Factors in Patients With Type 2 Diabetes Mellitus
    Sotiropoulos, Alexios
    Papazafiropoulou, Athanasia
    Kokolaki, Anthi
    Kardara, Marina
    Apostolou, Ourania
    Bousboulas, Stavros
    Pappas, Stavros
    DIABETES, 2013, 62 : A662 - A663
  • [37] Therapeutic education of patients with Type 2 diabetes mellitus and high cardiovascular risk
    Palfyorova, Ye. A.
    Orlov, V. A.
    RUSSIAN JOURNAL OF CARDIOLOGY, 2007, (06): : 72 - 75
  • [38] Polygenic risk scores for cardiovascular diseases and type 2 diabetes
    Wong, Chi Kuen
    Makalic, Enes
    Dite, Gillian S.
    Whiting, Lawrence
    Murphy, Nicholas M.
    Hopper, John L.
    Allman, Richard
    PLOS ONE, 2022, 17 (12):
  • [39] Cardiovascular Evaluation Of Patients With Type 2 Diabetes Mellitus
    Tudorica, Cornel Cezar
    Vintila, Ana Maria
    Tudorica, Steluta
    Calcan, Cristina
    Gurghean, Adriana
    Vintila, Vlad
    JOURNAL OF VASCULAR RESEARCH, 2017, 54 : 20 - 20
  • [40] Development and Validation of New Cardiovascular Disease Risk Scores for Patients With Diabetes Mellitus From a Pooled Cohort of the US Population
    Zhao, Yanglu
    D'Agostino, Ralph B.
    Bertoni, Alain G.
    Budoff, Matthew J.
    Correa, Adolfo
    Folsom, Aaron
    Jacobs, David R.
    Malik, Shaista
    Selvin, Elizabeth
    Watson, Karol E.
    Wong, Nathan D.
    CIRCULATION, 2019, 140